Dr. Xu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-7000Fax+1 617-632-2165
Summary
- Dr. Wenxin Xu is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Harvard Medical School and completed residency and fellowship training at Beth Israel Deaconess Medical Center. He specializes in genitourinary oncology.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
Harvard Medical SchoolClass of 2014
Certifications & Licensure
NH State Medical License 2022 - 2026
MA State Medical License 2014 - 2025
ME State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award Conquer Cancer Foundation, 2020
Publications & Presentations
PubMed
- 109 citationsOptimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort studyWenxin Xu, Saveli Goldberg, Maria Shubina, Alexander Turchin
BMJ. 2015-02-05 - 1214 citationsClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20 - 49 citationsAncestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha
Cancer Cell. 2022-10-10
Press Mentions
OncoHost Announces New Study on Biomarkers for Renal Cell CarcinomaJune 3rd, 2024- Dana-Farber Cancer Institute and OncoHost Partner for Renal Cell Carcinoma ResearchJune 13th, 2024
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
